Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07356154) titled 'A Study of Revumenib and Mezigdomide in People With Leukemia' on Jan. 20.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Leukemia
Acute Leukemia
Relapse Leukemia
Refractory Leukemia
Refractory Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Intervention:
Drug: Revumenib
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: January 16, 2026
Target...